Stock NUWE NUWELLIS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Nuwellis, Inc.

Equities

NUWE

US67113Y4052

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-21 EDT 		5-day change 1st Jan Change
0.21 USD -3.67% Intraday chart for Nuwellis, Inc. +7.58% -63.85%
06-06 Nuwellis Extends Pilot Program With Dialysis Services Provider DaVita MT
05-07 Top Midday Gainers MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Nuwellis Extends Pilot Program With Dialysis Services Provider DaVita
MT
Nuwellis and DaVita Extend Supply and Collaboration Agreement Pilot Phase
AQ
Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida
AQ
Nuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy
AQ
Top Midday Gainers
MT
Nuwellis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Transcript : Nuwellis, Inc., Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (NUWE) NUWELLIS Reports Q1 Revenue $1.9M, vs. Street Est of $2M
MT
Nuwellis, Inc. Announces First Quarter 2024 Financial Results
AQ
Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology
AQ
Nuwellis, Inc. Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology
CI
Nuwellis Announces Closing of $2.7 Million Public Offering
AQ
Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024
AQ
Maxim Downgrades Nuwellis to Hold
MT
Nuwellis Announces Pricing of $2.7 Million Public Offering
AQ
Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health
AQ
Nuwellis, Inc. Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health
CI
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference
AQ
Nuwellis, Inc. Announces Results from Two New Clinical Data Analyses from the AVOID-HF Trial, Which Demonstrate the Benefits of its Aquadex System in Reducing Heart Failure Readmissions at 30 Days
CI
Nuwellis, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NUWE Stock
  4. News Nuwellis, Inc.